GlassScriptPhysician profile
Benjamin Craig Matthews
NPI 1205372604
$12,936.88
in general payments reported to CMS, 2019-2025
29 companies · $2,956 in 2025
The $2,956 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,528 · 2022: $1,628 · 2023: $3,683 · 2024: $3,143 · 2025: $2,956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,361 · Education: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,360.89 |
| Education | $420.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,651.96 | 2021-2025 | Tremfya |
| Abbvie INC. | $2,382.37 | 2021-2025 | |
| Amgen INC. | $1,001.97 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $943.04 | 2021-2025 | |
| Pfizer INC. | $873.69 | 2022-2025 | |
| Ucb, INC. | $825.32 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $579.15 | 2021-2025 | Ilumya |
| Lilly USA, LLC | $539.99 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Organon LLC | $376.43 | 2023-2025 | Hadlima, Vtama |
| E.R. Squibb & Sons, L.L.C. | $331.57 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $252.83 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $229.45 | 2023-2025 | Siliq, Jublia, Cabtreo |
| Dermavant Sciences, INC. | $190.32 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $170.06 | 2021-2025 | Dupixent, Libtayo |
| Strata Skin Sciences, INC. | $84.90 | 2023-2025 | Xtrac |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $76.27 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Arcutis Biotherapeutics, INC. | $64.05 | 2025 | Zoryve |
| Sandoz INC. | $55.03 | 2024 | Hyrimoz |
| Organogenesis INC. | $48.74 | 2024 | |
| Incyte Corporation | $45.35 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $37.96 | 2025 | Nemluvio |
| Janssen Scientific Affairs, LLC | $34.95 | 2023 | Tremfya |
| Vyne Pharmaceuticals INC. | $25.14 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.89 | 2025 | Spevigo |
| Leo Pharma INC. | $24.19 | 2021 | |
| Fresenius Kabi USA, LLC | $20.53 | 2023 | Idacio |
| Genentech USA, INC. | $18.81 | 2021 | |
| Krystal Biotech INC | $14.49 | 2024 | Vyjuvek |
| Celltrion USA INC. | $13.43 | 2023 | Yuflyma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Matthews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.